SRC - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	ERRFI1	ERBB receptor feedback inhibitor 1
Novel	ESR1	estrogen receptor 1	Nuclear signaling by ERBB4 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Ovarian tumor domain proteases PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors RUNX1 regulates estrogen receptor mediated transcription ESR-mediated signaling RUNX1 regulates transcription of genes involved in WNT signaling Regulation of RUNX2 expression and activity Regulation of RUNX2 expression and activity Extra-nuclear estrogen signaling Estrogen-dependent gene expression Mitochondrial unfolded protein response (UPRmt) Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Diethylstilbestrol Chlorotrianisene Conjugated estrogens Desogestrel Levonorgestrel Progesterone Lindane Raloxifene Toremifene Medroxyprogesterone acetate Testosterone Mitotane Estrone Tamoxifen Hexachlorophene Estradiol Ethynodiol diacetate Dobutamine Clomifene Dienestrol Fulvestrant Norgestimate Ethinylestradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Oxybenzone Allylestrenol Zinc Genistein Prasterone Benzophenone Equilin Compound 19 Resveratrol Compound 18 Phthalic Acid Pyrazole Stanolone Naringenin Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Quercetin Afimoxifene 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estrone sulfate Quinestrol Phenolphthalein Permethrin Ospemifene AP1081 Custirsen NP-50301 CHF 4227 TAS-108 Lasofoxifene Arzoxifene Elacestrant Bazedoxifene Methyltestosterone beta-Naphthoflavone 17-METHYL-17-ALPHA-DIHYDROEQUILENIN din-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL Hexestrol dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate Erteberel N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol Tibolone Eugenol Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, B Polyestradiol phosphate Norethynodrel Octocrylene Homosalate Enzacamene Zeranol Ractopamine Gestrinone Estetrol Propyl Gallate Ormeloxifene 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol Testosterone cypionate Testosterone enanthate Stanolone acetate Estradiol acetate Estradiol benzoate Estradiol cypionate Estradiol dienanthate Estradiol valerate Zinc acetate Zinc chloride Zinc sulfate, unspecified form Estriol tripropionate Fluoroestradiol F-18
Novel	ESR2	estrogen receptor 2	PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ESR-mediated signaling Extra-nuclear estrogen signaling	Diethylstilbestrol Conjugated estrogens Progesterone Raloxifene Estrone Tamoxifen Estradiol Trilostane Estramustine Oxybenzone Genistein Prasterone Benzophenone Phthalic Acid Pyrazole Para-Mercury-Benzenesulfonic Acid Naringenin ICI-164384 5-Alpha-Androstane-3-Beta,17beta-Diol 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol Quercetin Afimoxifene Estriol Estrone sulfate MF101 CHF 4227 TAS-108 Lasofoxifene Arzoxifene Bazedoxifene Prinaberel ERB-196 [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 17alpha-Estriol (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one Erteberel (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL Eugenol Octocrylene Enzacamene Equol Estetrol Ormeloxifene 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol Estradiol acetate Estradiol benzoate Estradiol cypionate Estradiol dienanthate Estradiol valerate Estriol tripropionate Fluoroestradiol F-18
Novel	ETS1	ETS proto-oncogene 1, transcription factor	Oncogene Induced Senescence
Novel	ETS2	ETS proto-oncogene 2, transcription factor	Oncogene Induced Senescence
Novel	EVL	Enah/Vasp-like	Generation of second messenger molecules Signaling by ROBO receptors Signaling by ROBO receptors RHO GTPases Activate Formins
Novel	FANCC	FA complementation group C	Fanconi Anemia Pathway TP53 Regulates Transcription of DNA Repair Genes PKR-mediated signaling		Fanconi anemia
Novel	FARP2	FERM, ARH/RhoGEF and pleckstrin domain protein 2	SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion RAC1 GTPase cycle
Novel	FASLG	Fas ligand	Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited Interleukin-4 and Interleukin-13 signaling Dimerization of procaspase-8 FasL/ CD95L signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models FOXO-mediated transcription of cell death genes TNFs bind their physiological receptors		Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
Novel	FBP2	fructose-bisphosphatase 2	Gluconeogenesis
Novel	FBXO5	F-box protein 5	SCF-beta-TrCP mediated degradation of Emi1 Regulation of APC/C activators between G1/S and early anaphase Phosphorylation of Emi1 Mitotic Metaphase/Anaphase Transition G1/S-Specific Transcription
Novel	FGR	FGR proto-oncogene, Src family tyrosine kinase	FCGR activation Platelet sensitization by LDL Neutrophil degranulation FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis	Dasatinib Fostamatinib Zanubrutinib
Novel	FHIT	fragile histidine triad diadenosine triphosphatase		Adenosine monotungstate Ado-P-Ch2-P-Ps-Ado	Small cell lung cancer Non-small cell lung cancer
Novel	FLNA	filamin A	Platelet degranulation GP1b-IX-V activation signalling Cell-extracellular matrix interactions RHO GTPases activate PAKs OAS antiviral response	Artenimol	FG syndrome (FGS); Opitz-Kaveggia syndrome Periventricular nodular heterotopia (PVNH) Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS) Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia
Novel	FLT3	fms related receptor tyrosine kinase 3	PI3K Cascade PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling FLT3 Signaling FLT3 Signaling STAT5 Activation FLT3 mutants bind TKIs STAT5 activation downstream of FLT3 ITD mutants KW2449-resistant FLT3 mutants semaxanib-resistant FLT3 mutants crenolanib-resistant FLT3 mutants gilteritinib-resistant FLT3 mutants lestaurtinib-resistant FLT3 mutants midostaurin-resistant FLT3 mutants pexidartinib-resistant FLT3 mutants ponatinib-resistant FLT3 mutants quizartinib-resistant FLT3 mutants sorafenib-resistant FLT3 mutants sunitinib-resistant FLT3 mutants tandutinib-resistant FLT3 mutants linifanib-resistant FLT3 mutants tamatinib-resistant FLT3 mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Negative regulation of FLT3 FLT3 signaling through SRC family kinases FLT3 signaling through SRC family kinases FLT3 signaling by CBL mutants	Sorafenib Sunitinib XL999 Tandutinib Linifanib Lestaurtinib Midostaurin Ponatinib Nintedanib Pacritinib Tivozanib Fostamatinib Gilteritinib Brigatinib Fedratinib Amuvatinib Quizartinib Pexidartinib Pralsetinib	Acute myeloid leukemia (AML)
Novel	FMR1	fragile X messenger ribonucleoprotein 1			Premature ovarian failure Fragile X Syndrome, including: Fragile X Syndrome (FXS); Fragile X tremor/ataxia syndrome (FXTAS)
Novel	FOXO1	forkhead box O1	AKT phosphorylates targets in the nucleus Regulation of gene expression in beta cells AKT-mediated inactivation of FOXO1A Constitutive Signaling by AKT1 E17K in Cancer MAPK6/MAPK4 signaling Interleukin-4 and Interleukin-13 signaling Regulation of localization of FOXO transcription factors FOXO-mediated transcription of cell death genes FOXO-mediated transcription of cell death genes FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Regulation of FOXO transcriptional activity by acetylation Regulation of FOXO transcriptional activity by acetylation FOXO-mediated transcription of cell cycle genes FOXO-mediated transcription of cell cycle genes		Alveolar rhabdomyosarcoma
Novel	FRS2	fibroblast growth factor receptor substrate 2	PI3K Cascade PIP3 activates AKT signaling Frs2-mediated activation Frs2-mediated activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK2 signals through FRS2 and FRS3 RND2 GTPase cycle RND1 GTPase cycle Signaling by ALK fusions and activated point mutants
Novel	FYB1	FYN binding protein 1	Generation of second messenger molecules Generation of second messenger molecules Signal regulatory protein family interactions
Novel	FZR1	fizzy and cell division cycle 20 related 1	Autodegradation of Cdh1 by Cdh1:APC/C SCF-beta-TrCP mediated degradation of Emi1 APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase Phosphorylation of Emi1 Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Cyclin A/B1/B2 associated events during G2/M transition Cyclin A:Cdk2-associated events at S phase entry Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation

Search Results for: SRC